Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic Inflammatory Demyelinating Polyneuropathy.

Jonathan S. Katz1, David S. Saperstein

  • 1Department of Neurology, Palo Alto Veteran's Administration Hospital, 3801 Miranda Avenue, Palo Alto, CA 94304, USA. jskatz@stanford.edu

Current Treatment Options in Neurology
|August 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory Myopathies.

Current treatment options in neurology·2004
Same author

Myasthenia Gravis.

Current treatment options in neurology·2004
Same author

Peripheral Neuropathy Due to Cobalamin Deficiency.

Current treatment options in neurology·2002
Same author

Asymmetric Acquired Demyelinating Polyneuropathies: MMN and MADSAM.

Current treatment options in neurology·2001
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Choosing the best treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) remains controversial. Current evidence is limited by varying trial designs, making it difficult to definitively rank therapies like intravenous immunoglobulin or prednisone.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Therapeutics

Background:

  • Chronic inflammatory demyelinating polyneuropathy (CIDP) has several established treatments, including prednisone, intravenous immunoglobulin, and plasmapheresis.
  • Despite numerous randomized trials, significant variations in cost, side effect profiles, and administration methods contribute to ongoing debate regarding optimal first-line therapy.

Purpose of the Study:

  • To address the controversy surrounding the best therapeutic approach for CIDP.
  • To evaluate the limitations of existing clinical trials in guiding clinical practice decisions for CIDP management.

Main Methods:

  • Review of existing randomized controlled trials and case series on CIDP treatments.
  • Analysis of varying methodologies in previous CIDP studies, including dosage, duration, diagnostic criteria, and patient populations (newly diagnosed vs. treatment-experienced).

Related Experiment Videos

Main Results:

  • Close to 10 randomized trials demonstrate efficacy for prednisone, intravenous immunoglobulin, or plasmapheresis.
  • Existing trial data is difficult to directly compare due to inconsistent methodologies, hindering definitive conclusions on treatment superiority.
  • Immune-modulating agents like azathioprine and cyclophosphamide show promise in case series, typically as second-line options.

Conclusions:

  • The optimal first-line therapy for CIDP cannot be definitively determined from current evidence due to heterogeneity in clinical trial designs.
  • Second-line immune-modulating agents are often used for patients refractory to initial treatments, but robust data remains limited.
  • Further standardized research is needed to establish clear treatment guidelines for CIDP.